Resistant epilepsy in children: new drug opens hope after completing trials

A clinical trial in England presented encouraging results for children with a severe form of resistant epilepsy known as Dravetshowing marked reductions in seizure frequency and improvements in development. The news is immediately relevant because it opens the possibility of effective treatments for hundreds of genetic epilepsies without pharmacological options today.

The phase 2 study included 81 patients between 2 and 18 years old treated at the Great Ormond Street Hospitalin collaboration with the University College London. The minors received three doses of the experimental drug called Zorevunersen.

The results were conclusive: after the first administration the monthly frequency of seizures was reduced on average by around half, and after completing the three doses the reduction reached approximately 80%. Additionally, researchers reported that the treatment was well tolerated and no serious adverse effects were detected among participants.

Impact on daily life

Beyond the number of epileptic seizures, clinicians observed concrete changes in the children’s quality of life: advances in motor skills, improvement in communication and a greater ability to cope with the daily demands of the disease. For families living with Dravet – a condition estimated to affect around 3,000 children in England – this represents a tangible improvement in independence and development.

Lead author of the trial, Professor Helen Cross, Director of Childhood Epilepsy at the UCL Institute of Child Health, highlighted the seriousness of these genetic epilepsies: many patients require ongoing care and are at risk of sudden epilepsy-related death. For this reason, the team is already preparing a phase 3 trial that will evaluate the drug over a longer period to detect possible long-term adverse effects.

What it means for other genetic epilepsies

Outside experts considered the results an important proof of concept: If an antisense or other targeted therapy succeeds in reducing seizures and improving function in Dravet, that approach could be adapted to other monogenic forms of epilepsy.

Researcher Alfredo Gonzalez-Sulser, from the Institute for Neuroscience and Cardiovascular Research in Edinburgh, pointed out that there are more than 800 epilepsies of genetic origin that still lack specific therapies. In his opinion, these types of advances outline a clinical and regulatory route to develop interventions that benefit both patients and their caregivers.

• Essay size: 81 children from 2 to 18 years old.
• Tested drug: Zorevunersen, administered in three doses.
• Seizure reduction: ~50% after first dose; ~80% after three doses.
• Tolerance: well tolerated; no significant adverse effects were reported.
• Next steps: launch of a phase 3 trial to evaluate long-term efficacy and safety.

For the medical community and families, the finding is doubly relevant: it offers immediate hope for those living with Dravet and serves as a stimulus for research to advance in other genetic epilepsies. Even so, specialists remember that the data comes from a relatively small study and that only a large phase 3 will be able to confirm whether the benefit is maintained and is safe in the long term.

In practical terms, this could translate into fewer hospitalizations, less daily care burden, and better developmental prospects for hundreds or thousands of children if future trials confirm the results. For now, the focus is on completing and revising the next trial, and how to adapt similar strategies to other rare forms of epilepsy.

Similar items

Alonso Delgado covers the international news with rigor. You’ll find accurate and relevant reporting on major global events, from political crises to diplomatic breakthroughs.